Aspira Women's Health (AWH) 10-Q 12 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Oct. 31, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Registrant Name	VERMILLION, INC.
Entity Central Index Key	926,617
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		52,009,716

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 23,974	$ 22,965
Accounts receivable	68	167
Prepaid expenses and other current assets	411	526
Inventories	81
Total current assets	24,534	23,658
Property and equipment, net	765	508
Other assets	90	8
Total assets	25,389	24,174
Current liabilities:
Accounts payable	803	1,123
Accrued liabilities	2,245	2,201
Short-term debt		1,106
Deferred revenue		489
Other current liabilities	154
Total current liabilities	3,202	4,919
Lease obligation - long term	71
Total liabilities	$ 3,273	$ 4,919
Commitments and contingencies (Note 3)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at September 30, 2015 and December 31, 2014
Common stock, $0.001 par value, 150,000,000 shares authorized at September and December 31, 2014; 52,009,716 and 43,115,790 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	$ 52	$ 43
Additional paid-in capital	387,669	370,685
Accumulated deficit	(365,605)	(351,473)
Total stockholders' equity	22,116	19,255
Total liabilities and stockholders' equity	$ 25,389	$ 24,174

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	52,009,716	43,115,790
Common stock, shares outstanding	52,009,716	43,115,790

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Product		$ 330	$ 209	$ 1,500	$ 611
License			114	316	341
Total revenue		330	323	1,816	952
Cost of revenue:
Product		757	606	1,822	749
Total cost of revenue		757	606	1,822	749
Gross profit (loss)		(427)	(283)	(6)	203
Operating expenses:
Research and development	[1]	874	1,263	2,898	3,473
Sales and marketing	[2]	2,462	2,762	7,238	7,632
General and administrative	[3]	1,380	1,281	4,111	4,240
Total operating expenses		4,716	5,306	14,247	15,345
Loss from operations		(5,143)	(5,589)	(14,253)	(15,142)
Interest income		11	8	26	34
Other income (expense), net		(14)	(10)	95	(25)
Net loss		$ (5,146)	$ (5,591)	$ (14,132)	$ (15,133)
Net loss per share - basic and diluted		$ (0.10)	$ (0.16)	$ (0.31)	$ (0.42)
Weighted average common shares used to compute basic and diluted net loss per common share		50,297,031	35,913,580	45,483,889	35,865,089
[1]	(1) Research and development$ 44$ 32$ 107$ 103
[2]	(2) Sales and marketing 81 164 154 233
[3]	(3) General and administrative 420 159 648 518

Consolidated Statements Of Ope5

Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Research And Development [Member]
Stock-based compensation expense	$ 44	$ 32	$ 107	$ 103
Sales And Marketing [Member]
Stock-based compensation expense	81	164	154	233
General And Administrative [Member]
Stock-based compensation expense	$ 420	$ 159	$ 648	$ 518

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (14,132)	$ (15,133)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on extinguishment of debt	(37)
Non-cash license revenue	(316)	(341)
Depreciation and amortization	197	93
Stock-based compensation expense	908	832
Warrants issued for services		22
Changes in operating assets and liabilities:
Accounts receivable	99	194
Prepaid expenses and other assets	33	(564)
Inventories	(81)
Accounts payable, accrued liabilities and other liabilities	(278)	1,398
Deferred revenue	(173)	901
Net cash used in operating activities	(13,780)	(12,598)
Cash flows from investing activities:
Purchase of property and equipment	(222)	(232)
Net cash used in investing activities	(222)	(232)
Cash flows from financing activities:
Repayment of capital lease obligations	(5)
Repurchase of common stock	(1,291)
ssuance costs related to 2014 private placement	(122)
Proceeds from sale of common stock, net of issuance costs	17,496
Repayment of short-term debt	(1,069)
Proceeds from issuance of common stock from exercise of stock options	2	88
Net cash provided by financing activities	15,011	88
Net increase (decrease) in cash and cash equivalents	1,009	(12,742)
Cash and cash equivalents, beginning of period	22,965	29,504
Cash and cash equivalents, end of period	23,974	$ 16,762
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	2
Supplemental disclosure of noncash investing and financing activities:
Equipment acquired through capital lease agreements	107
Changes in other current liabilities related to equipment	$ 125

Organization, Basis Of Presenta

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	9 Months Ended
	Sep. 30, 2015
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	1. ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. In March 2010, the Company commercially launched OVA1™ risk of malignancy test for pelvic mass disease (“OVA1”). The Company distributed OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”) (see Note 2) through August 10, 2015. Since August 10, 2015, the Company has distributed all but a nominal number of OVA1 tests distributed through Quest Diagnostics through its wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”), which opened in June 2014. Liquidity The Company believes that its working capital position as of the date of the filing of this Quarterly Report on Form 10-Q will be sufficient to meet the Company’s working capital needs for at least the next 12 months. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The consolidated balance sheet at December 31, 2014 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2014, included in Vermillion’s Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on March 31, 2015. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results. Certain reclassifications of prior year amounts have been made to conform to current year presentation. Significant Accounting and Reporting Policies The Company has made no significant changes in its critical accounting policies and estimates from those disclosed in Vermillion’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 . In July 2015, the Financial Accounting Standards Board (the “ FASB ”) issued ASU No. 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory (“ ASU No. 2015-11 ”) . ASU 2015-11 changes the measurement of inventory from the lower of cost or market to the lower of cost and net realizable value. The amendments are effective prospectively for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2016. The Company do es not anticipate a material impact on its consolidated financial statements from the adoption of this ASU. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ ASU No. 2014-09 ”) . ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09. On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.

Agreements with Quest Diagnosti

Agreements with Quest Diagnostics Incorporated	9 Months Ended
	Sep. 30, 2015
Agreements With Quest Diagnostics Incorporated [Abstract]
Agreements With Quest Diagnostics Incorporated	2. AGREEMENTS WITH QUEST DIAGNOSTICS INCORPORATED In July 2005, the Company entered into a Strategic Alliance Agreement (as amended, the “Strategic Alliance Agreement”) with Quest Diagnostics to develop and commercialize diagnostic tests, including OVA1, from the Company’s product pipeline. In connection with the Strategic Alliance Agreement, the Company entered into a credit agreement with Quest Diagnostics, pursuant to which Quest Diagnostics provided the Company with a $10,000,000 secured line of credit to be used to pay for certain costs and expenses related to activities under the Strategic Alliance Agreement. This line of credit was collateralized by certain of the Company’s intellectual property assets. The credit agreement provided for the forgiveness of portions of the amounts borrowed under the secured line of credit upon the achievement of certain milestones related to the development, regulatory approval and commercialization of certain diagnostic tests. Through December 31, 2014, the entire loan was either repaid or forgiven except for $1,106,000 which was in dispute. The dispute regarding the balance of the loan was resolved on March 11, 2015 for a payment to Quest Diagnostics totaling $1,069,000 . As a result of this settlement, the Company recognized one-time items during the three months ended March 31, 2015, including product revenue of $163,000 , license revenue of $202,000 , gain on extinguishment of debt of $ 3 7,000 and reversal of other liabilities totaling $ 41 ,000 . Unrelated to the debt dispute described above, in August 2013, the Company sent Quest Diagnostics a notice of termination of the Strategic Alliance Agreement. Notwithstanding the termination, the Company agreed that Quest Diagnostics could continue to make OVA1 available to healthcare providers on the same financial terms following the termination while negotiating in good faith towards an alternative business structure. Quest Diagnostics disputed the effectiveness of the termination. Prior to the termination, Quest Diagnostics had the non-exclusive right to commercialize OVA1 on a worldwide basis, with exclusive commercialization rights in the clinical reference laboratory marketplace in the United States, India, Mexico, and the United Kingdom through September 2014, with the right to extend the exclusivity period for one additional year. On March 11, 2015, the Company reached a settlement agreement with Quest Diagnostics that terminated all disputes related to the Strategic Alliance Agreement and the Company’s prior loan agreement with Quest Diagnostics. The Company also entered into a new commercial agreement with Quest Diagnostics. Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 10, 2015, with the exception of a nominal number of OVA1 tests distributed through Quest Diagnostics after that date. Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 2017 in exchange for a market value fee. Per the terms of the new commercial agreement, the Company will not offer to existing or future Quest Diagnostics customers CA 125-II or other tests that Quest Diagnostics offers. On June 17, 2015, the Company entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) with Quest Diagnostics. Pursuant to the Share Repurchase Agreement, the Company purchased from Quest Diagnostics 860,595 shares of Vermillion common stock for a total purchase price of $1,290,892 , or $1.50 per share. The price per share was agreed to in principle in March 2015 and based upon a simple average of the closing prices per share of Vermillion common stock for a trailing 60 -day period at that time. This price was then reduced by a negotiated discount. Subsequently, the common stock repurchased from Quest Diagnostics was retired.

Commitments And Contingencies

Commitments And Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments And Contingencies [Abstract]
Commitments And Contingencies	3. COMMITMENT AND CONTINGENCIES The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease, including its principal facility and CLIA laboratory located near Austin, Texas. The Austin, Texas leases include an aggregate annual base rent of $130,000 and annual estimated common area charges, taxes and insurance of $62,000 and expire at various times prior to May 31, 2016 . On October 7, 2015, the Company entered a lease agreement for a facility in Trumbull, Connecticut. The lease includes initial payments for the buildout of leasehold improvements to the office space, which are estimated to be approximately $438,000 . The term of the lease is five years beginning after the initial date of occupancy and a rent abatement period of five months. The lease includes an aggregate annual base rent of $32,000 in addition to common area charges, taxes and insurance. In April 2015, the Company agreed to lease two laboratory instruments for a total initial payment of $250,000 and ongoing payments of approximately $7,000 per month for 36 months after delivery. The agreement also requires minimum annual purchases of reagents from the manufacturer of the equipment. As of September 30, 2015 , one instrument has been delivered and placed into service.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	4. STOCKHOLDERS’ EQUITY On July 17, 2015 the Company completed the sale of 9,602,500 shares of Vermillion common stock, including 1,252,500 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares , in an underwritten public offering at a price of $1.96 per share. The Company received net proceeds from the offering of $17,496,000 after deducting underwriting discounts and offering expenses. 2010 Stock Incentive Plan The Company’s employees, directors, and consultants are eligible to receive awards under the Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”). The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provides for issuance of up to 8,122,983 shares of Vermillion common stock under the 2010 Plan, subject to adjustment as provided in the 2010 Plan. Employee Stock-Based Compensation During the nine months ended September 30, 2015, the Company granted to the Company’s President and Chief Executive Officer options to purchase 400,000 shares of Vermillion common stock with an exercise price of $1.95 per share. These stock options vest in 48 equal monthly instalments from the date of the grant. During the nine months ended September 30, 2015, the Company also granted to certain Vermillion officers options to purchase 275,000 shares of Vermillion common stock with an exercise price of $2.08 and granted to certain Vermillion employees options to purchase 45,000 shares of Vermillion common stock with an exercise price of $1.77 . These stock options vest 25% on the first anniversary of the grant date, and the remaining stock options vest ratably over the following 36 -month period. During the nine months ended September 30, 2015, the Company granted to a Vermillion officer options to purchase 150,000 shares of Vermillion common stock with an exercise price of $1.74 per share. 25% of these stock options vest on the first anniversary of the grant date, and the remaining stock options vest ratably over the following 36 -month period. The Company also granted to officers and employees of the Company options to purchase 317,000 shares of Vermillion common stock with an exercise price of $2.03 per share. These stock options vest 25% on each of the four anniversaries of the grant date. The Company also granted to employees of the Company options to purchase 37,500 shares of Vermillion common stock with an exercise price of $2.05 per share. These stock options vest 25% on each of the four anniversaries of the grant date. In addition, the Company granted certain officers options to purchase 400,000 shares of Vermillion common stock with an exercise price of $2.03 per share with performance-based vesting based on certain metrics through December 31, 2016. During the nine months ended September 30, 2015, the Company awarded 181,369 shares of restricted stock under the 2010 Plan having a fair value of approximately $370,000 to Vermillion’s Board of Directors as stock-based payment for services rendered in 2015. 50% of these shares of restricted stock vested on July 13, 2015. 25% of these shares of restricted stock vested on September 1, 2015, and the remaining 25% will vest on December 1, 2015. During the nine months ended September 30, 2015, the Company awarded certain consultants of the Company options to purchase 50,000 shares of Vermillion common stock with an exercise price of $2.05 per share. These stock options vest in 24 equal monthly instalments from the date the consultant first provided services to the Company. The allocation of employee stock-based compensation expense by functional area for the three and nine months ended September 30, 2015 and 2014 was as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2015 2014 2015 2014 Research and development $ $ $ $ Sales and marketing General and administrative Total $ $ $ $

Loss Per Share

Loss Per Share	9 Months Ended
	Sep. 30, 2015
Loss Per Share [Abstract]
Loss Per Share	5 . LOSS PER SHARE The Company calculates basic loss per share using the weighted average number of common shares outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the weighted average number of shares of common stock outstanding and excludes the effects of 7,972,985 and 2,563,106 potential shares of common stock as of September 30, 2015 and 2014, respectively, that are anti-dilutive. Potential shares of common stock include incremental shares of common stock issuable upon the exercise of outstanding warrants and stock options.

Organization, Basis of Presen12

Organization, Basis of Presentation And Significant Accounting And Reporting Policies (Policy)	9 Months Ended
	Sep. 30, 2015
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization	Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. In March 2010, the Company commercially launched OVA1™ risk of malignancy test for pelvic mass disease (“OVA1”). The Company distributed OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”) (see Note 2) through August 10, 2015. Since August 10, 2015, the Company has distributed all but a nominal number of OVA1 tests distributed through Quest Diagnostics through its wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”), which opened in June 2014.
Liquidity	Liquidity The Company believes that its working capital position as of the date of the filing of this Quarterly Report on Form 10-Q will be sufficient to meet the Company’s working capital needs for at least the next 12 months.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The consolidated balance sheet at December 31, 2014 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2014, included in Vermillion’s Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on March 31, 2015. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results. Certain reclassifications of prior year amounts have been made to conform to current year presentation.
Significant Accounting And Reporting Policies	Significant Accounting and Reporting Policies The Company has made no significant changes in its critical accounting policies and estimates from those disclosed in Vermillion’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 . In July 2015, the Financial Accounting Standards Board (the “ FASB ”) issued ASU No. 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory (“ ASU No. 2015-11 ”) . ASU 2015-11 changes the measurement of inventory from the lower of cost or market to the lower of cost and net realizable value. The amendments are effective prospectively for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2016. The Company do es not anticipate a material impact on its consolidated financial statements from the adoption of this ASU. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ ASU No. 2014-09 ”) . ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09. On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Allocation of Stock-Based Compensation Expense by Functional Area	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2015 2014 2015 2014 Research and development $ $ $ $ Sales and marketing General and administrative Total $ $ $ $

Agreements With Quest Diagnos14

Agreements With Quest Diagnostics Incorporated (Details) - USD ($)	Jun. 17, 2015	Mar. 11, 2015	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Line of Credit Facility [Line Items]
Secured line of credit, liability								$ 1,106,000
Repayment of short-term debt						$ 1,069,000
Product			$ 330,000		$ 209,000	1,500,000	$ 611,000
License					$ 114,000	316,000	$ 341,000
Gain on extinguishment of debt						$ 37,000
Shares authorized for repurchase	$ 860,595
Total purchase price of shares acquired	$ 1,290,892
Shares acquired, price per share	$ 1.50
Trailing period						60 days
Quest Diagnostics [Member]
Line of Credit Facility [Line Items]
Quest Diagnostics provided secured line of credit			$ 10,000,000			$ 10,000,000
Secured line of credit, liability								$ 1,106,000
Repayment of short-term debt		$ 1,069,000
Product				$ 163,000
License				202,000
Gain on extinguishment of debt				37,000
Decrease to other current liabilities				$ 41,000

Commitments And Contingencies (

Commitments And Contingencies (Details)	1 Months Ended	9 Months Ended	12 Months Ended
	Apr. 30, 2015USD ($)item	Sep. 30, 2015USD ($)item	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Commitments And Contingencies [Line Items]
Number of purchased laboratory instruments | item	2
Initial payment of laboratory equipment	$ 250,000
Monthly payment for acquisition for equipment	$ 7,000
Number of payments for purchase production of assets		36 months
Laboratory instruments delivered and placed into service | item		1
Austin, Texas facility [Member]
Commitments And Contingencies [Line Items]
Annual estimated common area charges, taxes and insurance		$ 62,000
Lease expiration date		May 31, 2016
Austin, Texas facility [Member] | Forecast [Member]
Commitments And Contingencies [Line Items]
Annual base rent				$ 130,000
Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Leasehold improvements		$ 438,000
Lease term		5 years
Rent abatement period		5 months
Trumbull, Connecticut Facility [Member] | Forecast [Member]
Commitments And Contingencies [Line Items]
Annual base rent			$ 32,000

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($)	Jul. 17, 2015	Sep. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued	9,602,500	52,009,716	43,115,790
Shares issued to underwriters	1,252,500
Price per share	$ 1.96	$ 0.001	$ 0.001
Proceeds from sale of common stock, net of issuance costs	$ 17,496,000
Common stock, par value	$ 1.96	$ 0.001	$ 0.001
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant		8,122,983
2010 Stock Incentive Plan [Member] | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares awarded		181,369
Fair value of restricted shares awarded		$ 370,000
2010 Stock Incentive Plan [Member] | Restricted Stock | July 13, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		50.00%
2010 Stock Incentive Plan [Member] | Restricted Stock | September 1, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | Restricted Stock | December 1, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | $2.05 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		37,500
Stock options granted, average exercise price		$ 2.05
2010 Stock Incentive Plan [Member] | $2.05 [Member] | Year One Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | $2.05 [Member] | Year Two Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | $2.05 [Member] | Year Three Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | $2.05 [Member] | Year Four Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | President and Chief Executive Officer [Member] | $1.95 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		400,000
Stock options granted, average exercise price		$ 1.95
Stock options vesting period		48 months
2010 Stock Incentive Plan [Member] | Vermillion Officers [Member] | $2.08 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		275,000
Stock options granted, average exercise price		$ 2.08
2010 Stock Incentive Plan [Member] | Certain Vermillion Employees [Member] | $1.77 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		45,000
Stock options granted, average exercise price		$ 1.77
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vesting period		36 months
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member] | $2.03 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		317,000
Stock options granted, average exercise price		$ 2.03
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member] | $2.03 [Member] | Year One Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member] | $2.03 [Member] | Year Two Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member] | $2.03 [Member] | Year Three Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member] | $2.03 [Member] | Year Four Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | Certain Officers [Member] | $2.03 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		400,000
Stock options granted, average exercise price		$ 2.03
2010 Stock Incentive Plan [Member] | Certain Consultants [Member] | $2.05 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		50,000
Stock options granted, average exercise price		$ 2.05
Stock options vesting period		24 months
2010 Stock Incentive Plan [Member] | Officer [Member] | $1.74 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		150,000
Stock options granted, average exercise price		$ 1.74
Stock options vesting period		36 months
2010 Stock Incentive Plan [Member] | Officer [Member] | $1.74 [Member] | Year One Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%

Stockholders' Equity (Allocatio

Stockholders' Equity (Allocation of Employee Stock-Based Compensation Expense By Functional Area) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 44	$ 32	$ 107	$ 103
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	81	164	154	233
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	420	159	648	518
Employee Stock-Based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	542	355	906	819
Employee Stock-Based Compensation [Member] | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	44	32	107	103
Employee Stock-Based Compensation [Member] | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	81	164	154	233
Employee Stock-Based Compensation [Member] | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 417	$ 159	$ 645	$ 483

Loss Per Share (Details)

Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Loss Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	7,972,985	2,563,106